Dr Richard Finn on PD 0332991 Plus Letrozole in ERPositive Breast Cancer

>> DOWNLOAD LINK 🎞️ #1 <<

>> DOWNLOAD LINK 🎞️ #2 <<

>> COPY / PASTE LINK PLEASE 🎵 MP3 <<

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=214YrLgo_oE

Richard Finn, MD, Division of Hematology/Oncology at the Jonsson Comprehensive Cancer Center, University of California, Los Angeles, describes results from a phase II study that examined PD 0332991, an oral selective inhibitor of cyclin-dependent kinase 4/6, in combination with letrozole as a first-line treatment for postmenopausal women with metastatic ER-positive breast cancer. • To view more coverage from SABCS, visit http://www.onclive.com/conference-cov...

#############################